Corroborating the above findings, another study by Zhang et al. revealed that PGAM1 suppression in triple-negative breast cancer (TNBC) synergizes with anti–PD–1 immunotherapy to diminish breast cancer cell survival [178]. Here, PGAM1 is linked to breast carcinoma.